Sirona Biochem Announces Jacques Cousteau's Son and Grandson as Brand Ambassadors
March 27 2014 - 7:45AM
Marketwired
Sirona Biochem Announces Jacques Cousteau's Son and Grandson as
Brand Ambassadors
VANCOUVER, BC--(Marketwired
- March 27, 2014) - Sirona Biochem Corp. (TSX-VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that
Jean-Michel Cousteau and Fabien Cousteau (son and grandson of
Jacques Cousteau) will become Brand Ambassadors for the
Company. A formal Brand Ambassador launch event has been
scheduled for April 8, 2014 at TFChem in Val de Reuil, France.
As Brand Ambassadors for Sirona Biochem, Jean-Michel Cousteau
and Fabien Cousteau will publicize our partnership's alliance and
goals to industry experts, commercial partners and investors.
Sirona Biochem will contribute its cosmetic, pharmaceutical and
scientific expertise and Sirona will become a primary scientific
resource for the potential commercialization of new ocean resources
in collaboration with the Cousteaus. The Cousteaus and Sirona also
share the goal of establishing a new accreditation for consumer
packaged goods to validate technologies that are safe both for
consumers and our fragile environments.
The launch event is scheduled to include a tour of the TFChem
laboratory followed by a reception for attendees. Notable attendees
are expected to include members of the French government,
pharmaceutical and cosmetic industry leaders, and media
representatives. This event is by invitation only.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in France
and is the recipient of multiple French national scientific awards
and European Union and French government grants. For more
information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
For more information regarding this press release, contact:
Christopher Hopton, CFOSirona Biochem Corp.
Phone: 1.604.282.6064Email: chopton@sironabiochem.com
Sirona Biochem (PK) (USOTC:SRBCF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sirona Biochem (PK) (USOTC:SRBCF)
Historical Stock Chart
From Jul 2023 to Jul 2024